Cargando…

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS

Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits of lenvatinib. Therefore, understanding the m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Jun, Zhu, Peng, Ye, Zhi, Wang, Mengke, Yang, Haijun, Huang, Shiqiong, Shu, Yan, Zhang, Wei, Zhou, Honghao, Li, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517968/ https://www.ncbi.nlm.nih.gov/pubmed/34658879 http://dx.doi.org/10.3389/fphar.2021.744578

Ejemplares similares

Biallelic variants in YRDC cause a developmental disorder with progeroid features
por: Schmidt, Julia, et al.
Publicado: (2021)

The universal YrdC/Sua5 family is required for the formation of threonylcarbamoyladenosine in tRNA
por: El Yacoubi, Basma, et al.
Publicado: (2009)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Dual-Responsive Core Crosslinking Glycopolymer-Drug Conjugates Nanoparticles for Precise Hepatocarcinoma Therapy
por: Wu, Jing, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
por: Rimini, M., et al.
Publicado: (2021)

Lenvatinib resistance mechanism and potential ways to conquer
por: Bo, Wentao, et al.
Publicado: (2023)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

YRDC is upregulated in non-small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis
por: Shen, Haibo, et al.
Publicado: (2020)

The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma
por: Fruytier, Anne-Catherine, et al.
Publicado: (2016)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
por: Wang, Cong-Cong, et al.
Publicado: (2023)

Defects in t(6)A tRNA modification due to GON7 and YRDC mutations lead to Galloway-Mowat syndrome
por: Arrondel, Christelle, et al.
Publicado: (2019)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
por: Li, Xiaomi, et al.
Publicado: (2023)

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
por: Jing, Zheng, et al.
Publicado: (2023)

Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats
por: Du, Xiaoyue, et al.
Publicado: (2023)

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
por: Xie, Qing-Yun, et al.
Publicado: (2022)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
por: Liu, Juanfang, et al.
Publicado: (2021)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
por: He, Ying, et al.
Publicado: (2023)

Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections
por: Sun, Bao, et al.
Publicado: (2021)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
por: Zhou, Nan, et al.
Publicado: (2023)

Compound Kushen Injection Protects Skin From Radiation Injury via Regulating Bim
por: Zheng, Jianxiao, et al.
Publicado: (2021)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
por: Jeannot, Victor, et al.
Publicado: (2016)

SPAG9 is involved in hepatocarcinoma cell migration and invasion via modulation of ELK1 expression
por: Yan, Qiuyue, et al.
Publicado: (2016)

A Bivalent Securinine Compound SN3-L6 Induces Neuronal Differentiation via Translational Upregulation of Neurogenic Transcription Factors
por: Liao, Yumei, et al.
Publicado: (2018)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy
por: Wang, Bin, et al.
Publicado: (2023)

Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest
por: Yan, Xia, et al.
Publicado: (2023)

Xinmailong Modulates Platelet Function and Inhibits Thrombus Formation via the Platelet αIIbβ3-Mediated Signaling Pathway
por: Wang, Huawei, et al.
Publicado: (2019)

A novel circular RNA circRBMS3 regulates proliferation and metastasis of osteosarcoma by targeting miR-424-eIF4B/YRDC axis
por: Gong, Zhe, et al.
Publicado: (2023)

Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer
por: Lin, Bo, et al.
Publicado: (2020)

A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer
por: Luo, Kangjia, et al.
Publicado: (2022)

Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
por: Guo, Libin, et al.
Publicado: (2022)

Comparation of differences in the performance of corporate social responsibility between Chinese and American pharmaceutical enterprises—based on corporate social responsibility report
por: Xu, HongHao, et al.
Publicado: (2023)

Total Flavonoids of Scutellaria barbata Inhibit Invasion of Hepatocarcinoma via MMP/TIMP in Vitro
por: Dai, Zhi-Jun, et al.
Publicado: (2013)

Anti-Obesity Effect of Fermented Panax notoginseng Is Mediated Via Modulation of Appetite and Gut Microbial Population
por: Shin, Na Rae, et al.
Publicado: (2021)

Modulation of Hepatocarcinoma Cell Morphology and Activity by Parylene-C Coating on PDMS
por: Pereira-Rodrigues, Nazaré, et al.
Publicado: (2010)

Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
por: Miyazaki, Katsuki, et al.
Publicado: (2023)

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
por: Luo, Lian-Xiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jup9qcn1ahoomagd1cpm4vnbtt